Data compiled by Redley Lamar · ChainSifter Intelligence
1Suppliers
6Customers
1Debt Items
0Related Chains
Source-Backed Evidence Depth
Cardiol Therapeutics Inc. (CRDL) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
9Total relationships
1Distinct source URLs
3High confidence
0.716Average confidence
2026-10-28Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Cardiol Therapeutics Inc. Suppliers
Ticker
Name
Confidence
Evidence
DALTON
DALTON
92%
Dalton has the manufacturing capability for Cardiol’s clinical trial materials, scalable to support all stages of the drug development process (Phase I, II, III, and commercial).
Cardiol Therapeutics Inc. Customers
Ticker
Name
Confidence
Evidence
ALTEROLA-BIOTECH-INC
ALTEROLA-BIOTECH-INC
62%
d journals. He currently divides his time between his clinical and academic activities at The Methodist Hospital and ITESM. Prior to being appointed to Cardiol’s Board of Directors, Dr. Torre-Amione …
COMMON-SHARES-THE-CORPORATION
COMMON-SHARES-THE-CORPORATION
62%
nabinoid-based treatments. The parties with which the Corporation does business may perceive that they are exposed to reputational risk as a result of the Corporation’s cannabinoid-related activities…
CORPORATION-THE-CORPORATION
CORPORATION-THE-CORPORATION
62%
a manufacturer and distributor of products designed to be ingested by humans, the Corporation faces an inherent risk of exposure to product liability claims, regulatory action, and litigation if its …
INCORPORATION-THE-CORPORATION
INCORPORATION-THE-CORPORATION
62%
nabinoid-based treatments. The parties with which the Corporation does business may perceive that they are exposed to reputational risk as a result of the Corporation’s cannabinoid-related activities…
SARBANES-OXLEY-ACT-THE-CORPORATION
SARBANES-OXLEY-ACT-THE-CORPORATION
62%
nabinoid-based treatments. The parties with which the Corporation does business may perceive that they are exposed to reputational risk as a result of the Corporation’s cannabinoid-related activities…
U-S-EXCHANGE-ACT-THE-CORPORATION
U-S-EXCHANGE-ACT-THE-CORPORATION
62%
nabinoid-based treatments. The parties with which the Corporation does business may perceive that they are exposed to reputational risk as a result of the Corporation’s cannabinoid-related activities…
Cardiol Therapeutics Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
CRDL-DEBT
Debt stack $84,384
90%
Market cache reports total debt of $84,384.
Cardiol Therapeutics Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Cardiol Therapeutics Inc..
Cardiol Therapeutics Inc. Ownership
Holder
Name
Confidence
Evidence
CRDL-OWNER-MMCAP-INTERNATIONAL-INC-SPC
MMCAP International Inc. SPC
90%
13F overlay lists MMCAP International Inc. SPC as top holder; 46 tracked holders.
Cardiol Therapeutics Inc. Extended Supply Chain Network
No secondary connectionsNo correlated companies found through shared supply chain relationships.
